PAA (ASX) PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III

Originally posted by kpax ↑

Hi All,

Well we have the WHO today, declare a new variant of concern "omicron".

The world market has taken notice. FTSE down 3.6% Oil down 13% Nasdaq and Dow Jones both 2% + down. Moderna 20% up.

So from a science perspective let's take a look at why.

Omicron is different to Delta in that it has two furin cleavage sites which increases its RNA ability to fuse with our ACE 2 receptors. In other words the protein spike on the virus has increased by a factor of possibly two. Making it more transmissible. Tom Peacock a Virologist at the Imperial College of London Department of Infections says " it is really awful". He also states that Omicron is genetically worse than any variant of Covid to date.

Ref : iflscience.com
New Covid-19 variant may be "worse than nearly anything else about " Warn Scientists. Nov 2021.

So how does this affect Pharmaust.
As most of we share holders know we have a significant royalty interest in Bromac which was on sold by Pharmaust to a private company.

Why is Bromac so special in relation to Omicron.

Remember you heard this on HC first !

We already have Monepantel that is already scientifically proven to interfere with the stage 3 of the Covid cell reproduction cycle once it is in the body. ( Covid 19 has four particular reproduction cycles). That is excellent.

But , what of Bromac. Well, it interferes with the ACE 2 receptors in our body to not link up with the virus once it enters our bodies. The ACE 2 receptors (or enzymes) are the first contact our cells have with Covid.

What is highly interesting to me. Is that Bromac and N Acetylcysteine have been studied to have a double impact on Covid. In that N Acetylcysteine is a potent mTOR inhibitor as well as a potent anti-inflammatory component thus negating the cytokine storm.

But the best part, is that Bromac can enter the double furin cleavage site of Omicron.

Have a look at this study to corroborate the above statements.

Ref : The Combination of Bromelain and Acetylcysteine ( Bromac) synergistically inactivates SARS-CoV-2.
Akhter/Morris 2021.

To be specific it's all about breaking down the glycans. Which Bromac does.

Are we looking at the demise of Covid ?
I will let you be the judge.

Read this study to see why the virus needs glycans.

Ref : Beyond Shielding : The Roles of Glycans in the SARS-CoV-2 Spike Protein. Caslalino et al . 2021

So is Acetylcysteine safe. You bet it is.
Is Bromac safe . Ditto.

Disclaimer : I take one medication per day . Yes, it's Acetylcysteine. Why as an anti oxidant and for its properties as an mTOR inhibitor as well as for its properties in relation to autophagy .
It is not a script based medicine and there is no patent involved.

Is this double combination the cure for Omicron ?

Some of the informed people who own this stock have told me personally that they would have no hesitation to take Monepantel if they acquired Covid 19. Soon some may also include Bromac in their medication repitoire.

Cheers All.

Expand

Kpax, thank you for the further interesting insights! My only question is, when are we going to see serious action to bring BOTH Bromac and Monepantel to countless millions the world over? Both because it may indeed help so many people survive Covid and in the process, get some big DOLLARS flowing to PAA shareholders?

No.	Vol.	Price($)
2	7234	19.0¢

No.

Vol.

Price($)

7234

19.0¢

Price($)	Vol.	No.
19.5¢	260069	3

Price($)

Vol.

No.

19.5¢

260069

No.	Vol.	Price($)
2	7234	0.190
10	211175	0.185
13	301185	0.180
3	284030	0.175
2	174892	0.170

No.

Vol.

Price($)

7234

0.190

211175

0.185

301185

0.180

284030

0.175

174892

0.170

Price($)	Vol.	No.
0.195	260069	3
0.200	348393	9
0.205	222000	3
0.210	238902	5
0.215	255948	3

Price($)

Vol.

No.

0.195

260069

0.200

348393

0.205

222000

0.210

238902

0.215

255948

(20min delay)
Last 19.5¢		Change 0.000(0.00%)		Mkt cap ! $94.81M

Open	High	Low	Value	Volume
19.5¢	19.5¢	19.0¢	$212.6K	1.118M

PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-17

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GreenX picks up prospective copper project in Germany

Venture to sniff out high-grade REE targets at Jupiter project, WA

Westgold sets its sights on top five producer status through merger with Karora

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Is oil undervalued?

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-17

Top Stories

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GreenX picks up prospective copper project in Germany

Venture to sniff out high-grade REE targets at Jupiter project, WA

Westgold sets its sights on top five producer status through merger with Karora

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Is oil undervalued?

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News